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Expression of the Vanin Gene Family in Normal and
Inflamed Human Skin: Induction by Proinflammatory
Cytokines
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Gys J. de Jongh1, Mieke Bergers1, Geuranne S. Tjabringa1, Patrick L.J.M. Zeeuwen1 and Joost Schalkwijk1
The vanin gene family encodes secreted and membrane-bound ectoenzymes that convert pantetheine into
pantothenic acid and cysteamine. Recent studies in a mouse colitis model indicated that vanin-1 has
proinflammatory activity and suggest that pantetheinases are potential therapeutic targets in inflammatory
diseases. In a microarray analysis of epidermal gene expression of psoriasis and atopic dermatitis lesions, we
identified vanin-3 as the gene showing the highest differential expression of all annotated genes that we studied
(19-fold upregulation in psoriasis). Quantitative real-time PCR analysis confirmed the microarray data on vanin-3
and showed similar induction of vanin-1, but not of vanin-2, in psoriatic epidermis. Immunohistochemistry
showed that vanin-3 is expressed in the differentiated epidermal layers. Using submerged and organotypic
keratinocyte cultures, we found that vanin-1 and vanin-3 are induced at the mRNA and protein level by
psoriasis-associated proinflammatory cytokines (Th17/Th1) but not by Th2 cytokines. We hypothesize that
increased levels of pantetheinase activity are part of the inflammatory-regenerative epidermal differentiation
program, and may contribute to the phenotype observed in psoriasis.
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INTRODUCTION
The human vanin gene family consists of thee genes, vanin-1
(VNN1), vanin-2 (VNN2) and vanin-3 (VNN3), which are
located on chromosome 6q22-24 (Galland et al., 1998;
Martin et al., 2001). These genes show a similar structure
consisting of seven exons, and encode proteins with a high
degree of homology (B65% sequence identity) (Granjeaud
et al., 1999). Human vanin-1 and vanin-2 being membrane-
associated ectoenzymes and vanin-3 being a secreted
enzyme. Vanins are conserved among species, and two mice
orthologs (vanin-1 and vanin-3, but not vanin-2) have been
identified (Granjeaud et al., 1999). To the best of our
knowledge, vanin-1 was first described as a regulator of the
late adhesion steps in the thymus homing in mice (Aurrand-
Lions et al., 1996). Human vanin-2 was characterized as a
molecule involved in the regulation of adherence and
migration of neutrophils (Suzuki et al., 1999). Subsequent
studies identified vanins as enzymes that are involved in the
coenzyme A synthesis. Their enzymatic activity catalyzes the
conversion of pantetheine into pantothenic acid (vitamin B5,
a coenzyme A precursor) and into the antioxidant cysteamine
(Maras et al., 1999; Martin et al., 2001). In mice deficient for
vanin-1, no free cysteamine was found in tissues, suggesting
that at least in mice, vanin-1 is a major pantetheinase (Pitari
et al., 2000). These mice show decreased non-steroidal anti-
inflammatory drugs (NSAID)- and Schistosoma-induced
intestinal inflammation, which can be completely reversed
by oral administration of cystamine, the oxidized form of
cysteamine (Martin et al., 2004). Vanin-1 deficiency is also
able to control colitis in the 2,4,6-trinitrobenzene sulfonic
acid colitis model (Berruyer et al., 2006). Another biological
activity of cysteamine is its presumed antagonism of the
peroxisome proliferator-activated receptor-g (PPAR-g). On
the basis of these findings, it was proposed that vanin-1 is an
epithelial sensor of stress that exerts a dominant control over
innate immune responses in mouse tissue (Berruyer et al.,
2006). Therefore, the pantetheinase activity of vanin family
members could be a previously unidentified therapeutic
target in inflammatory diseases.
Psoriasis vulgaris and atopic dermatitis are two common
chronic inflammatory skin diseases, characterized by various
different clinical and histological features depending on the
stage of the disease. Both diseases are generally regarded as
immune-mediated conditions involving activated T cells and
cytokines of the Th1/Th17 type (psoriasis) or of the Th2 type
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(atopic dermatitis) (Leung and Bieber, 2003; Nickoloff et al.,
2007; Nograles et al., 2008). In lesional psoriatic skin,
increased levels of proinflammatory cytokines (such as IL-1,
tumor necrosis factor-a (TNF-a), IFN-g, IL-6, IL-8, IL-17, and
IL-22) are found. These cytokines, which are produced by
T-cells, dendritic cells, and/or keratinocytes, can act both on
immunocytes and on keratinocytes. Activation of keratino-
cytes by these cytokines induces specific gene expression
profiles, which include secretion of antimicrobial proteins
and chemokines (Zeeuwen et al., 2008). In addition to the
role of the adaptive immune system, recent genetic studies
have indicated the importance of abnormalities in epithe-
lium-expressed genes as a primary cause. Loss-of-function
alleles of the skin barrier protein filaggrin were found to be a
major predisposing factor for atopic dermatitis (Palmer et al.,
2006), and we have recently shown that copy number
variation of a b-defensin gene cluster was associated with
increased risk for psoriasis (Hollox et al., 2008). The
differences in gene expression between the lesional psoriatic
epidermis and the lesional atopic dermatitis epidermis have
been investigated by various methods (Nomura et al., 2003;
de Jongh et al., 2005; Zeeuwen et al., 2008). Using a
microarray approach on purified epidermis, we identified
183 genes as differentially expressed between psoriasis and
atopic dermatitis (de Jongh et al., 2005). These data are
accessible through GEO Series accession number GSE6601
(http://www.ncbi.nlm.nih.gov/geo). It is remarkable that we
identified vanin-3 as the gene showing the highest differential
expression of all annotated genes that we studied (unpub-
lished data). As there was no information on the expression of
vanin family members in human epidermis, and vanin-1 has
been recently described as a potential drug target in
inflammatory bowel disease, we decided to investigate the
expression and induction of vanin-3 and other vanin family
members in human epidermal keratinocytes in vivo and
in vitro. Our results suggest that vanin-1 and vanin-3 could be
relevant mediators in Th17/Th1-drived inflammatory skin
conditions.
RESULTS
High expression levels of vanin-1 and vanin-3 in lesional
psoriatic skin
The transcriptome of epidermal sheets of lesional epidermis
from psoriasis and atopic dermatitis was analyzed using high-
density oligonucleotide arrays as described earlier (GEO
Series accession number GSE6601). All known human vanin
genes were present on the microarray. Vanin-1 and vanin-3
were detectable in all 12 samples, whereas vanin-2 was
detected in none of them. Vanin-3 showed the highest
upregulation (19-fold) of the annotated genes on the array in
psoriasis compared with that in atopic dermatitis. Further-
more, vanin-1 was found to be relatively overexpressed in
psoriasis (2.3-fold). Microarray data were confirmed by
quantitative real-time PCR (qPCR) analysis on mRNA from
lesional skin of psoriatic patients and of atopic dermatitis
patients, and normal skin of healthy volunteers. Figure 1
shows that vanin-3 expression is high in psoriatic epidermis,
but low in normal skin and atopic dermatitis. Vanin-1
expression was strongly induced in psoriasis patients and
moderately in atopic dermatitis patients as compared with
that in normal skin. Although vanin-2 expression was
significantly induced in both psoriasis and atopic dermatitis,
vanin-2 expression is very low compared with vanin-1 and
vanin-3.
As there is little quantitative information on relative
expression levels of human vanin family members in most
organs, we carried out qPCR on a large panel of tissues,
including many epithelia, to allow comparison with the
epidermis. Figure 2 shows the expression of the vanin genes
in different tissues. The highest expression levels of vanin-3
were found in the liver and blood, being of similar magnitude
as found in psoriatic epidermis. Other tissues where vanin-3
expression was found are the urethra, the lymph nodes, parts
of the respiratory tract, and most parts of the gastrointestinal
tract. Vanin-2 expression was found in almost all tissues, but
by far the highest expression was found in the spleen and
blood. In lesional psoriatic epidermis, vanin-2 expression was
near the average expression. Vanin-1 was mainly expressed
in the same tissues as vanin-3, but relatively high expression
was found in the spleen, kidney, and blood. In lesional
psoriatic epidermis, vanin-1 expression was of the same
magnitude as that in the kidney and liver.
Vanin-3 protein is expressed by differentiated keratinocytes
To investigate which cellular compartment of the epidermis
express vanins, we performed immunohistochemical staining
on normal skin, atopic dermatitis skin, and on psoriatic skin.
As there were no commercial antisera available that were
suitable for immunohistochemistry, we expressed recombi-
nant vanin-3 as a TrXA fusion protein, which was used to
raise a polyclonal antiserum in rabbits. Figure 3 shows that
epidermal vanin-3 protein expression is largely confined to
differentiated keratinocytes, both in normal and in psoriatic
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Figure 1. Analysis of vanin mRNA in healthy, psoriasis and atopic dermatitis
skin.Quantitative real-time PCR for vanin-1, vanin-2, and vanin-3 was carried
out on RNA of epidermal sheets from skin biopsies of healthy controls (n¼ 7),
psoriatic patients (n¼ 9), and atopic dermatitis patients (n¼6). Expression of
target genes was normalized to that of RPLP0. For graphical representation, all
values were expressed relative to vanin-1 in normal skin, which was set at
unity (Livak and Schmittgen, 2001). Primer sequences and efficiency of
amplification are given in Table 1. Vanin-1, vanin-2, and vanin-3 expression
is induced in both psoriasis and atopic dermatitis as compared with that in
normal skin. Values are presented as mean and SD. One-way ANOVA
*Po0.001.
2168 Journal of Investigative Dermatology (2009), Volume 129
PAM Jansen et al.
Expression of Vanin-1 and Vanin-3 in Psoriatic Skin
epidermis. Vanin-3 expression in normal and atopic derma-
titis epidermis is restricted to the stratum granulosum,
whereas in psoriatic epidermis, strong vanin-3 expression is
also found in the stratum spinosum. Dermal vanin-3
expression was limited to endothelial cells and to a small
proportion of the cellular infiltrate.
Induction of vanin expression by cytokines
The psoriasis-specific induction of vanin-1 and vanin-3
suggested that psoriasis-associated cytokines could be
involved in vanin gene regulation. We have shown earlier
that in vitro stimulation of cultured normal keratinocytes by
the mixtures of psoriasis-associated cytokines (IFN-g, TNF-a,
and IL-1 herein further referred to as Th1 cytokines) or by
atopic dermatitis-associated cytokines (IL-4 and IL-13, herein
further referred to as Th2 cytokines) results in disease-specific
gene expression in these cells. Figure 4 shows the expression
of vanin-1 and vanin-3 by submerged cultures of human
keratinocytes stimulated with cytokines. The cytokine mix-
tures and concentrations were chosen based on earlier
experiments to establish optimal concentrations for induction
of a psoriatic phenotype (expression of b-defensin-2 (hBD-2)
and elafin) or of an atopic dermatitis phenotype (expression
of carbonic anhydrase II) (Kamsteeg et al., 2007; Zeeuwen
et al., 2008). We found that both vanin-1 and vanin-3
expressions are induced after Th1 cytokine stimulation.
Vanin-2 is not upregulated after cytokine stimulation (data
not shown). Th2 cytokines did not have a significant effect on
the expression of any of the vanin genes. In addition, we also
tested the Th17 cytokines, IL-17 and IL-22. Both vanin-1 and
vanin-3 expressions were increased upon stimulation with IL-
17, but not after IL-22 stimulation, which has only a small
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Figure 2. mRNA expression of vanin family members in normal human tissues. Quantitative real-time PCR was performed on RNA of normal human tissues.
Expression of target genes was normalized to that of RPLP0. For graphical representation, all values were expressed relative to vanin-1 in the tongue, which was
set at unity, to allow comparison of the expression levels between tissues and genes (Livak and Schmittgen, 2001). Normal human tissues are from one
individual. Values from epidermis (at least six biopsies) are given for comparison.
Figure 3. Immunolocalization of vanin-3 in normal, atopic dermatitis, and psoriasis skin. Immunohistochemical staining of normal skin (a) and of lesional
skin of an atopic dermatitis patient (b) and of a psoriasis patient (c) with a polyclonal rabbit antiserum against recombinant vanin-3. Expression of
vanin-3 in normal skin and atopic dermatitis skin was limited to the stratum granulosum, whereas in psoriasis skin, strong vanin-3 expression was found in
multiple layers of the stratum spinosum. Bar¼100 mm. Control sections stained with pre-immune serum were virtually negative (see insets).
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stimulatory effect on vanin-1 expression. A combination of
Th1 cytokines and Th17 cytokines resulted in a strong
synergistic induction of both vanin-1 and vanin-3 expres-
sions, which were of similar magnitude as found in vivo in
psoriatic epidermis (data not shown).
Induction of vanin-1 and vanin-3 in reconstructed human
epidermis by cytokines
We have recently described a reconstructed skin model, in
which we could induce a psoriatic phenotype (as witnessed
by expression of the surrogate markers hBD-2 and elafin) by
the addition of psoriasis-associated cytokines. We found that
in these reconstructed skin models, the addition of IFN-g was
dispensable, whereas IL-6 strongly potentiated the effect of
IL-1a and TNF-a (Tjabringa et al., 2008). For this reason, we
used cytokine mixtures of TNF-a, IL-1a, and IL-6 or
individual Th17 cytokines, such as IL-17 and IL-22, to
examine the effect on vanin gene induction. Here, these
constructs were stimulated with various cytokines to inves-
tigate the induction of vanins. Using qPCR analysis, we found
similar effects of psoriasis- and atopic dermatitis-associated
cytokines on vanin expression as found in submerged
cultures (Figure 5). Both IL-17 and the mixture of TNF-a,
IL-1a, and IL-6 induced strong vanin-1 and vanin-3 expres-
sion. IL-22 induced a weak, nonsignificant expression of
vanin-1 and vanin-3. Th2 cytokine mix did not induce vanin-
1, whereas it showed a small but nonsignificant increase in
vanin-3 expression. Immunohistochemical staining of these
skin constructs confirmed the qPCR results, showing a strong
induction of vanin-3 staining in the upper epidermal layers
of cultures stimulated with IL-17 or with the mix of TNF-a,
IL-1a, and IL-6 (Figure 6).
DISCUSSION
Using microarray analysis, qPCR, and immunohistochemi-
stry, we have analyzed expression of the vanin gene family,
which has not been reported earlier in skin. Expression of
vanin-1 and vanin-3 was shown to be a part of the
inflammatory-regenerative differentiation program that is
characteristic for psoriasis. High expression levels of
vanin-1 and vanin-3 could be induced by psoriasis-
associated proinflammatory cytokines in submerged and
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Figure 4. Induction of vanin expression in submerged culture by
proinflammatory cytokines. Quantitative real-time PCR of vanin-1 and
vanin-3 was carried out on RNA obtained from submerged cultured
keratinocytes after stimulation with various combinations of proinflammatory
cytokines and compared with non-stimulated keratinocytes (n¼6).
Concentrations of cytokines were optimized earlier for induction of psoriasis-
like phenotypes in vitro. Vanin-1 and vanin-3 expression was strongly
induced by the Th1 cytokine mixture (IFN-g, TNF-a, and IL-1a n¼6) and by
IL-17 (n¼ 5). IL-22 (n¼ 5) induces vanin-1 expression, but not vanin-3
expression. A Th2-cytokine mixture (IL-4 and IL-13 n¼5) has no effects on
vanin expression. A mixture of all cytokines showed a strong, synergistic
induction of vanin expression (n¼5). Repeated measures ANOVA *Po0.05
and **Po0.005.
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Figure 5. Induction of vanin expression in reconstructed skin by
proinflammatory cytokines. Quantitative real-time PCR of vanin-1 and
vanin-3 expression was carried out on RNA obtained from reconstructed skin
after stimulation with various combinations of proinflammatory cytokines and
compared with non-stimulated reconstructed skin (n¼ 5). Here, we used a
cytokine mixture containing TNF-a, IL-1a, and IL-6 based on earlier
experiments for optimal induction of a psoriatic phenotype in vitro in
reconstructed skin. Both this cytokine mixture (n¼ 2) and IL-17 alone (n¼ 3)
strongly induced vanin-1 and vanin-3 expression. The Th2 cytokine mixture
(n¼2) and the Th17 cytokine IL-22 (n¼3) had no effects on vanin expression.
One-way ANOVA *Po0.05 and **Po0.005.
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air-exposed keratinocyte cultures. In vitro reconstructed skin
can be used as a model for further study of the role of vanins
in epidermal biology.
Apart from studies on gene structure, very little is known
regarding human vanin gene expression at the mRNA and
protein level. A putative function of vanin-2 in cell adherence
has been reported for human neutrophils, and recently the
expression of vanin splice forms has been reported in these
cells (Nitto et al., 2008). The existence of splice variants in
the pantetheinase gene family suggested the possibility of
alternative roles in addition to their enzymatic activity. Most
functional data on vanin family members (predominantly
vanin-1) come from studies in knockout mice (see the
Introduction section). From these mouse studies, vanins
emerge as a class of enzymes that can have both proin-
flammatory and protective effects. Although there is no
information at this moment whether increased vanin-1 and
vanin-3 expression leads to increased levels of metabolites
(cysteamine, pantothenic acid) in psoriatic epidermis, we
would argue that this could possibly contribute to the skin
abnormalities observed in psoriasis, as will be discussed in
the following.
In this study, we have found that vanin-3 is expressed in
differentiated keratinocytes. Although the exact function of
vanins in the skin remains to be elucidated, it is attractive to
speculate about a role of vanins in terminal differentiation.
The products of the vanin-mediated enzymatic conversion of
pantetheine are pantothenic acid and cysteamine. Pantothe-
nic acid, a precursor of coenzyme A, is involved in the
epidermal lipid synthesis. In normal human epidermis, high
levels of lipid synthesis are found in both the basal layer and
the stratum granulosum (Monger et al., 1988). Lipids are
important for skin barrier function, as they are part of the
lamellar bodies formed by keratinocytes in the stratum
spinosum (Elias, 2005). The contents of lamellar bodies are
secreted into the extracellular spaces and transformed into
lamellar bilayers to form an impermeable, lipid-containing
sheet that serves as a water barrier. The increased expression
of vanins in psoriatic epidermis could reflect the increased
requirement of precursors to keep up with the lipid synthesis
that is necessary to compensate the increased keratinocyte
turnover (that is, shortened half-life) in psoriasis. Notwith-
standing this potentially increased supply of lipid precursors,
the skin barrier function in psoriasis is abnormal with respect
to water loss (Grice and Bettley, 1967). This could be due to
the biochemical activity of cysteamine, the other metabolite
of the vanin-mediated enzymatic conversion of pantetheine.
Cysteamine is a strong transglutaminase (TGase) inhibitor by
its binding to an important cysteine residue in the active site
of the enzyme (Jeon et al., 2004; Candi et al., 2005). In skin,
TGase-1, TGase-3, and TGase-5 are the major TGases that
catalyze the formation of e-(g-glutamyl)lysine bonds between
cornified envelope precursor proteins (Polakowska et al.,
1991; Kim et al., 1993; Candi et al., 2002). TGases play an
important role in normal skin development, and they are
expressed at different stages of epidermal differentiation and
at different levels within the epidermis. In psoriatic skin,
TGase-5 expression is unaffected, whereas it has been shown
that TGase-3 expression is slightly downregulated (Candi
et al., 2002). The expression of TGase-1 is shifted from the
granular layer in normal skin to the suprabasal spinous layer
in psoriatic skin (Nonomura et al., 1993). As most studies
only determine the presence of TGase enzymes and not their
activity within the tissue, this does not provide information on
a possible effect of epidermal cysteamine. Some authors
argue that TGase activity in psoriasis is increased (Bernard
et al., 1986; Esmann et al., 1989), but these findings are
mainly based on ex vivo experiments, where endogenous
epidermal cysteamine could easily be washed away resulting
in active TGase proteins in their assays. In a recent study by
Harrisson et al. the effect of TGase inhibitors in a
reconstructed skin model has been studied. Interestingly,
they found that TGase inhibition caused a psoriatic pheno-
type in vitro, including hyperproliferation, parakeratosis, and
cytokeratin 16 expression, which are hallmarks of the disease
(Harrison et al., 2007). These findings support a role for
vanin-dependent cysteamine production in the pathogenesis
of the disease.
Another enzyme whose activity is inhibited by cysteamine
is caspase-3 (Lesort et al., 2003). This enzyme is activated
during terminal differentiation of keratinocytes. In normal
skin, caspase-3 is involved in both nuclear loss and
correct filaggrin processing (Weil et al., 1999). Addition of
caspase-3 inhibitors to reconstructed skin models prevents
nuclei to be degraded, which may lead to parakeratosis (Weil
et al., 1999). Also the alteration of filaggrin processing as a
result of caspase-3 inhibition could contribute to a disturbed
skin barrier as found in psoriasis and atopic dermatitis.
Speculatively, increased cysteamine levels caused by vanin-1
and vanin-3 overexpression could inhibit the caspase-3
Figure 6. Immunohistochemical staining of vanin-3 in reconstructed skin.
Reconstructed skin, with or without cytokine stimulation, was stained for
vanin-3 using a polyclonal rabbit antiserum against recombinant vanin-3.
Control cultures (a) or Th2 cytokine-stimulated cultures (c) showed a weak
expression of vanin-3, predominantly in the upper differentiated layers.
Stimulation with a cytokine mixture of TNF-a, IL-1a, and IL-6 (b) or with IL-17
(d) results in the strong expression of vanin-3 in the upper differentiated layers.
Bar¼100 mm. Control sections stained with pre-immune serum were virtually
negative (see insets).
www.jidonline.org 2171
PAM Jansen et al.
Expression of Vanin-1 and Vanin-3 in Psoriatic Skin
activity, thereby contributing to the phenotypic changes, such
as parakeratosis and compromised skin barrier, seen in
psoriasis.
Finally, cysteamine is reported to be an antagonist for PPAR-g
(Berruyer et al., 2006). In human epidermis, PPARs (PPAR-a,
PPAR-b/d and PPAR-g) are important ligand-activated transcrip-
tion factors that are involved in the maintenance of skin
homeostasis by inhibiting epidermal cell growth, promoting
epidermal terminal differentiation, and regulating skin inflam-
matory responses (Michalik and Wahli, 2007). These properties
make PPARs interesting molecules with respect to psoriasis and
other inflammatory skin disorders. In psoriasis, the epidermal
expression of PPAR-a and PPAR-g is decreased, suggesting a role
for these proteins (Rivier et al., 1998). In the last few years,
PPAR-g activators have been used as an antipsoriatic drug; PPAR
agonists thiazolidinedione and its derivatives rosiglitazone and
pioglitazone have shown to be beneficial for psoriasis patients
(Ellis et al., 2000; Bongartz et al., 2005; Robertshaw and
Friedmann, 2005). In a murine model, also the thiazolidinedione
derivatives ciglitazone and troglitazone improve skin home-
ostasis (Demerjian et al., 2006). The exact role of PPAR-g in
psoriasis is still not completely clear, but increased levels of an
endogenous antagonist such as cysteamine could explain the
positive effects of these PPAR-g activators.
As cysteamine is a potent antioxidant and skin is exposed to
oxidative stress, vanins could very well have a role in these
processes. Surprisingly, vanin-1 knockout mice, which lack
cysteamine in tissues where vanin-1 is predominantly ex-
pressed, display resistance to systemic oxidative stress caused
by paraquat administration or a lethal dose of g-irradiation. This
effect was ascribed to increased levels of glutathione, an even
more potent antioxidant, in the liver of these knockout mice
and was reversible after administration of cysteamine. Some
papers argue that oxidative stress plays a role in the
pathogenesis of psoriasis (Shilov and Sergienko, 2000; Wojas-
Pelc and Marcinkiewicz, 2007), and it has also been reported
that there is insufficient antioxidant activity in psoriatic lesions
(Yildirim et al., 2003). In plasma of psoriatic patients, the total
plasma antioxidant capacity was increased compared with
healthy individuals (Rocha-Pereira et al., 2004), which could
be the result of increased vanin expression in lesional skin
leading to increased levels of cysteamine. One of the functions
of the stratum corneum implies antioxidant defense, but most
oxidative stress was found in the dermis and basal layers of
psoriatic skin (mon-Gadal et al., 2000). Vanin expression was
predominantly found in the stratum granulosum and stratum
spinosum, indicating a possible role in the antioxidant defense
against reactive oxygen species generated by exogenous
mechanisms (e.g. UV light) rather than by endogenous reactive
oxygen species.
In conclusion, to the best of our knowledge, this is the first
report describing the strongly increased expression of vanin-1
and vanin-3 in psoriatic skin. However, many questions
remain to be answered regarding the function of vanins in
normal and psoriatic skin. Induction of vanin expression as a
part of the inflammatory-regenerative differentiation program
of human epidermis could be a beneficial response to supply
the skin with antioxidant activity and sufficient pantothenic
acid to restore skin barrier function. Alternatively, cysteamine
could, by its inhibitory activity toward TGases and caspase-3,
and its antagonistic activity toward PPAR-g, contribute to the
pathology observed in lesional skin, which is clearly an area
for future research.
MATERIALS AND METHODS
Human tissues
Biopsies of normal human skin, psoriatic lesions, and atopic
dermatitis lesions were performed under local anesthesia with
4mm punches. Psoriasis biopsies were performed in the centre of a
chronique plaque. All samples were collected with written informed
consent using protocols that comply with the Declaration of
Helsinki Principles. Permission for these studies was obtained
from the medical ethics committee (Commissie Mensgebonden
Onderzoek Arnhem-Nijmegen). Archival autopsy material was
obtained from the Department of Pathology (University of Nijmegen,
The Netherlands).
Submerged keratinocyte cultures
Primary human keratinocytes obtained from biopsies of healthy
volunteers, psoriasis patients, and atopic dermatitis patients were
cultured following the Rheinwald–Green system (Rheinwald and
Green, 1975) and stored in liquid nitrogen until use. First-passage
cells were cultured to confluency in keratinocyte growth medium
and induced to differentiate by growth factor depletion as described
earlier (Van Ruissen et al., 1996; Pfundt et al., 1996). Differentiating
cell cultures were stimulated with a mix of 10Uml1 IFN-g,
30 ngml1 TNF-a, and 30 ngml1 IL-1a (referred to as Th1 cytokine
mix); a mix of 50 ngml1 IL-4 and 50 ngml1 IL-13 (referred to as
Th2 cytokine mix); and 30 ngml1 IL-17, 30 ngml1 IL-22, a
combination of IL-17, IL-22, and the Th1 cytokine mix, or left
untreated (control) (Zeeuwen et al., 2008). IL-1a, TNF-a, IL-4, IL-13,
IL-17, and IL-22 were obtained from Peprotech (London, UK) and
IFN-g from HyCult Biotechnology (HBT, Uden, The Netherlands).
The cells were harvested after 48 hours for mRNA isolation.
Three-dimensional reconstructed skin
Reconstructed skin was generated as described earlier (Tjabringa
et al., 2008). Briefly, de-epidermized human dermis of 0.8mm
thickness and 8mm diameter was used as a scaffold for keratinocytes
in tissue culture inserts in a 24-well plate. These were cultured
submerged for 3 days, and subsequently the medium level was
lowered to allow air exposure to induce terminal differentiation.
After 7 days of air exposure, a fully stratified epidermis has
developed that expresses all normal differentiation markers, but is
negative for psoriasis-associated genes, such as cytokeratin 16
(CK16), elafin and hBD-2. At this point, a mixture of proinflamma-
tory cytokines (10 ngml1 IL-1a, 5 ngml1 TNF-a, and 5 ngml1
IL-6), Th2 cytokines (50 ngml1 IL-4 and 50 ngml1 IL-13), or Th17
cytokines (100 ngml1 IL-17 or 100 ngml1 IL-22) is added for 72
hours, which induces cytokine-specific gene expression. IL-6 was
obtained from Gentaur (Brussels, Belgium). Two different donors of
human keratinocytes were used.
Quantitative real-time PCR
Epidermal sheets from skin biopsies or skin constructs were
separated from the underlying dermis according to earlier described
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protocols (Van Ruissen et al., 2002; Tjabringa et al., 2008). RNA
extracted from 26 different normal human tissues, punch biopsies,
and cultured human keratinocytes was used for first-strand cDNA
synthesis using the iScript cDNA synthesis kit (Bio-Rad, Hercules,
CA) according to the manufacturer’s recommendation with an input
of 1mg of RNA. The reverse transcriptase product was used as a
template for quantitative real-time PCR amplification of genes of
interest using the MyiQ Single-Color Real-Time Detection System for
quantification with SYBR Green and melting curve analysis (Bio-
Rad). Expression of the target genes, vanin1, vanin-2 and vanin-3,
was normalized to that of the housekeeping gene human ribosomal
phosphoprotein P0 (RPLP0). Primer sequences (Biolegio, Nijmegen,
The Netherlands) and efficiency of amplification are given in
Table 1.
Vanin-3 antibody production
A vanin-3 PCR product from cDNA derived from cultured
keratinocytes was cloned into pET-32a vector (Novagen, Madison,
WI), expressed as a TrxA-Vanin-3 fusion protein in Escherichia coli.
The fusion protein was emulsified with complete Freund’s adjuvant
to immunize rabbits to generate polyclonal serum. Animals were
boostered with TrxA-Vanin-3, and blood was obtained for serum
preparation. Pre-immune serum was drawn for control staining in
immunohistochemistry.
Immunohistochemistry
Human skin biopsies and human reconstructed skin were fixed in
buffered 4% formalin for 4 hours and processed for routine histology.
Subsequently, the reconstructed skin was embedded in paraffin and
6mm-thick sections were cut. Sections were processed for staining
using an indirect immunoperoxidase technique with avidin–biotin
complex enhancement. All procedures have been described earlier
in detail (Le et al., 1996). Vanin-3 staining was performed using
vanin-3 antibody raised in rabbit as a primary antibody and a goat-
anti-rabbit antibody as a secondary antibody (Vector Laboratories,
Burlingame, CA). As a control, also the pre-immune serum was used
in the same dilution (1:500) as the vanin-3 antibody.
Statistics
Data are expressed as mean±s.d. Statistical analysis of qPCR data
was carried out on deltaCt values using SPSS software (release 16.0,
SPSS, Chicago, IL). One-way analysis of variance (ANOVA) and
repeated measures ANOVA were performed, followed by post hoc
testing corrected for multiple testing (Bonferroni). P-values ofo0.05
were considered statistically significant.
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